Verastem Inc (VSTM)
2.69
+0.08
(+3.07%)
USD |
NASDAQ |
Sep 27, 16:00
2.68
-0.01
(-0.37%)
After-Hours: 20:00
Verastem SG&A Expense (Annual): 30.73M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 30.73M |
| December 31, 2022 | 24.98M |
| December 31, 2021 | 24.12M |
| December 31, 2020 | 62.76M |
| December 31, 2019 | 101.21M |
| December 31, 2018 | 77.26M |
| December 31, 2017 | 21.38M |
| Date | Value |
|---|---|
| December 31, 2016 | 17.22M |
| December 31, 2015 | 17.63M |
| December 31, 2014 | 18.16M |
| December 31, 2013 | 15.47M |
| December 31, 2012 | 10.52M |
| December 31, 2011 | 3.815M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
24.12M
Minimum
2021
101.21M
Maximum
2019
48.76M
Average
30.73M
Median
2023
SG&A Expense (Annual) Benchmarks
| Sage Therapeutics Inc | 274.52M |
| SeaStar Medical Holding Corp | 8.237M |
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 15.29M |
| iBio Inc | 11.67M |